Drug Executive Collapses During Oval Office Announcement
During a press conference in the Oval Office, a drug executive collapsed while President Donald Trump announced a partnership to lower obesity drug prices. The event was abruptly cut short when the man, identified as Gordon Findlay, Novo Nordisk's global brand director, fainted.
Details of the Incident
President Trump was speaking alongside representatives from Eli Lilly and Novo Nordisk about a new deal to expand coverage and reduce prices for obesity treatments Zepbound and Wegovy. David Ricks, Eli Lilly's CEO, noticed the incident and asked,
“Are you OK? Gordon, are you OK?”
Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, was present and assisted Findlay as he collapsed to his knees.
Response to the Emergency
After the executive fainted, the press was quickly asked to leave the room. Health and Human Services Secretary was also present during the incident but no further details about Findlay's condition were disclosed at the time.
Context of the Announcement
- The announcement involved a pricing deal with Eli Lilly and Novo Nordisk.
- Focused on making obesity drugs more affordable and accessible.
- Key drugs mentioned were Zepbound and Wegovy.
President Donald Trump looks on as Administrator for the Centers for Medicare & Medicaid Services Dr. Mehmet Oz and others assist Gordon Findlay.
Author's summary: A Novo Nordisk executive fainted during President Trump's announcement of a drug pricing deal, prompting immediate medical assistance and ending the press event early.